Sun Pharma on Saturday reported a 15% increase in its third quarter sales to Rs 15,469 crore, while net profit was up 16% year-on-year to Rs 3,368 crore, driven by growth across its branded businesses in India, emerging markets and global innovative medicines. “Our innovative product offering has expanded further with the launch of Unloxcyt…
The Indian market ended higher on Friday, with the Sensex and Nifty climbing decisively as a strong earnings surprise from Infosys reignited risk appetite and pulled heavyweight IT stocks sharply higher, among other factors. The rally pushed the Sensex and Nifty to fresh intraday highs, reversing recent caution and setting a bullish tone for the…
Sector outperformer, Torrent Pharmaceuticals, has delivered 1-year returns of 16. It has another 14% upside, says this brokerage. Company’s PAT rose 16% YoY while its revenue increased 9% over the corresponding quarter of the last financial year.Buy Sun Pharma at Rs 1,805 | Target: Rs 1,968 | Upside: 9%Sun Pharmaceutical Industries’ 12-month returns stand at…
1/5 Market overview post-expiry Market expert Aamar Deo Singh in an interview with ET Now said that following the recent expiry, market sentiment appears cautious, primarily due to geopolitical concerns such as the recent terror attack in Kashmir. While earlier, markets were reacting to global trade-related news like tariffs, that influence has now reduced. Notably,…
April 1, 2025April 1, 2025 India’s pharmaceutical industry is on the rise, with its top companies becoming key players on the global stage. Behind their success lies a blend of innovation, cutting-edge research, and a drive to improve healthcare worldwide—making them a force to be reckoned with. In this…
Sun Pharma reported a 28% year-on-year (YoY) jump in net profit to Rs 3040 crore in Q2FY25 led by higher sales growth in domestic formulation and global specialty portfolio. The company reported net profit of Rs 2375.5 crore during the corresponding quarter of the previous year. Revenue rose 10.5% YoY to Rs. 13,264 crore in…
Pharma major Sun Pharma is expected to report healthy revenue growth during the second quarter, driven by its domestic business, which benefits from favorable seasonality and growing volumes. Revenue from operations is likely to jump 10% year-on-year (YoY), according to the average estimate of four brokerages. Meanwhile, net profit for the quarter is projected to…